March 11, 2020
Janssen Pharmaceutical said on March 10 that it has filed an application in Japan for its anti-CD38 monoclonal antibody Darzalex (daratumumab) seeking approval for its triplet therapy with carfilzomib and dexamethasone for the treatment of recurrent/refractory multiple myeloma. In addition,...read more